{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:52:28Z","timestamp":1792306348337,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40273-019-00825-1","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T22:02:18Z","timestamp":1564092138000},"page":"1305-1312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-3163","authenticated-orcid":false,"given":"Seamus","family":"Kent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talitha","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Tran-Duy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Schlackow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Lizheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendelin","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lamotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"825_CR1","doi-asserted-by":"publisher","first-page":"j2816","DOI":"10.1136\/bmj.j2816","volume":"357","author":"B Goldacre","year":"2017","unstructured":"Goldacre B. The WHO joint statement from funders on trials transparency. BMJ. 2017;357:j2816. \nhttps:\/\/doi.org\/10.1136\/bmj.j2816\n\n.","journal-title":"BMJ"},{"key":"825_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Gopalan R, Berlin JA, et al. Publication bias in clinical research. Lancet. 1991;337:867\u201372. \nhttps:\/\/doi.org\/10.1016\/0140-6736(91)90201-Y\n\n.","journal-title":"Lancet"},{"key":"825_CR3","doi-asserted-by":"publisher","first-page":"e1002049","DOI":"10.1371\/journal.pmed.1002049","volume":"13","author":"JPA Ioannidis","year":"2016","unstructured":"Ioannidis JPA. Why most clinical research is not useful. PLoS Med. 2016;13:e1002049. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1002049\n\n.","journal-title":"PLoS Med"},{"key":"825_CR4","doi-asserted-by":"publisher","first-page":"f105","DOI":"10.1136\/bmj.f105","volume":"346","author":"I Chalmers","year":"2013","unstructured":"Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published. BMJ. 2013;346:f105. \nhttps:\/\/doi.org\/10.1136\/bmj.f105\n\n.","journal-title":"BMJ"},{"key":"825_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13059-015-0669-2","volume":"16","author":"M Watson","year":"2015","unstructured":"Watson M. When will \u2018open science\u2019 become simply \u2018science\u2019? Genome Biol. 2015;16:101. \nhttps:\/\/doi.org\/10.1186\/s13059-015-0669-2\n\n.","journal-title":"Genome Biol"},{"key":"825_CR6","unstructured":"Hill S, Velazquez A, Tay-Teo K, et al. 2015 Global Survey on Health Technology Assessment by National Authorities. WHO 2015."},{"key":"825_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","volume":"6","author":"MJ Buxton","year":"1997","unstructured":"Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217\u201327. \nhttps:\/\/doi.org\/10.1002\/(SICI)1099-1050(199705)6:3%3c217:AID-HEC267%3e3.0.CO;2-W\n\n.","journal-title":"Health Econ"},{"key":"825_CR8","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00002","author":"National Institute for Health and Clinical Excellence","year":"2013","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Nice. 2013. \nhttps:\/\/doi.org\/10.2165\/00019053-200826090-00002\n\n.","journal-title":"Nice"},{"key":"825_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/emj.19.4.301","volume":"19","author":"S Goodacre","year":"2002","unstructured":"Goodacre S. Being economical with the truth: how to make your idea appear cost effective. Emerg Med J. 2002;19:301\u20134. \nhttps:\/\/doi.org\/10.1136\/emj.19.4.301\n\n.","journal-title":"Emerg Med J"},{"key":"825_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10198-013-0471-6","volume":"14","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ. 2013;14:367\u201372. \nhttps:\/\/doi.org\/10.1007\/s10198-013-0471-6\n\n.","journal-title":"Eur J Health Econ"},{"key":"825_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/0272989X18798833","volume":"38","author":"PJ Neumann","year":"2018","unstructured":"Neumann PJ, Kim DD, Trikalinos TA, et al. Future directions for cost-effectiveness analyses in health and medicine. Med Decis Mak. 2018;38:767\u201377. \nhttps:\/\/doi.org\/10.1177\/0272989X18798833\n\n.","journal-title":"Med Decis Mak"},{"key":"825_CR12","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/s0168-8227(00)00217-5","volume":"50","author":"JB Brown","year":"2000","unstructured":"Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract. 2000;50:S57\u201364. \nhttps:\/\/doi.org\/10.1016\/s0168-8227(00)00217-5\n\n.","journal-title":"Diabetes Res Clin Pract"},{"key":"825_CR13","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc07-9919","volume":"30","author":"AJ Palmer","year":"2007","unstructured":"Palmer AJ, Mount Hood 5 Modeling Group, Clarke P, et al. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting (ADA WORKGROUP REPORT) (Conference notes). Diabetes Care. 2007;30:1638\u201346. \nhttps:\/\/doi.org\/10.2337\/dc07-9919\n\n.","journal-title":"Diabetes Care"},{"key":"825_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","volume":"16","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting. Value Health. 2013;16:670\u201385. \nhttps:\/\/doi.org\/10.1016\/j.jval.2013.01.002\n\n.","journal-title":"Value Health"},{"key":"825_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jval.2018.02.002","volume":"21","author":"AJ Palmer","year":"2018","unstructured":"Palmer AJ, Si L, Tew M, et al. Computer modeling of diabetes and its transparency: a report on the eighth Mount Hood challenge. Value Health. 2018;21:724\u201331. \nhttps:\/\/doi.org\/10.1016\/j.jval.2018.02.002\n\n.","journal-title":"Value Health"},{"key":"825_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Mak. 2012;32:733\u201343. \nhttps:\/\/doi.org\/10.1177\/0272989X12454579\n\n.","journal-title":"Med Decis Mak"},{"key":"825_CR17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/MLR.0000000000000811","volume":"55","author":"JT Cohen","year":"2017","unstructured":"Cohen JT, Wong JB. Can economic model transparency improve provider interpretation of cost-effectiveness analysis? A response. Med Care. 2017;55:912\u20134. \nhttps:\/\/doi.org\/10.1097\/MLR.0000000000000811\n\n.","journal-title":"Med Care"},{"key":"825_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00019053-200624090-00002","volume":"24","author":"DM Eddy","year":"2006","unstructured":"Eddy DM. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics. 2006;24:837\u201344. \nhttps:\/\/doi.org\/10.2165\/00019053-200624090-00002\n\n.","journal-title":"Pharmacoeconomics"},{"key":"825_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jval.2013.06.015","volume":"16","author":"P Vemer","year":"2013","unstructured":"Vemer P, Krabbe PFM, Feenstra TL, et al. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force. Value Health. 2013;16:1106\u20137. \nhttps:\/\/doi.org\/10.1016\/j.jval.2013.06.015\n\n.","journal-title":"Value Health"},{"key":"825_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361. \nhttps:\/\/doi.org\/10.1007\/s40273-015-0327-2\n\n.","journal-title":"Pharmacoeconomics"},{"key":"825_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0272989X11408730","volume":"31","author":"KM Kuntz","year":"2011","unstructured":"Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Mak. 2011;31:530\u20139. \nhttps:\/\/doi.org\/10.1177\/0272989X11408730\n\n.","journal-title":"Med Decis Mak"},{"key":"825_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jval.2016.10.016","volume":"20","author":"M Hoogendoorn","year":"2017","unstructured":"Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker MRMM. External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the Third COPD Modeling Meeting. Value Health. 2017;20:397\u2013403.","journal-title":"Value Health"},{"key":"825_CR23","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30\u00a0year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925\u201333. \nhttps:\/\/doi.org\/10.1007\/s00125-013-2940-y\n\n.","journal-title":"Diabetologia"},{"key":"825_CR24","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1136\/heartjnl-2016-310970","volume":"103","author":"I Schlackow","year":"2017","unstructured":"Schlackow I, Kent S, Herrington W, et al. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart. 2017;103:1880\u201390. \nhttps:\/\/doi.org\/10.1136\/heartjnl-2016-310970\n\n.","journal-title":"Heart"},{"key":"825_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s41669-017-0019-2","volume":"1","author":"CJ Sampson","year":"2017","unstructured":"Sampson CJ, Wrightson T. Model registration: a call to action. Pharmacoeconom Open. 2017;1:73\u20137. \nhttps:\/\/doi.org\/10.1007\/s41669-017-0019-2\n\n.","journal-title":"Pharmacoeconom Open"},{"key":"825_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/11537580-000000000-00000","volume":"28","author":"RJG Arnold","year":"2010","unstructured":"Arnold RJG, Ekins S. Time for Cooperation in health economics among the modelling community. Pharmacoeconomics. 2010;28:609\u201313. \nhttps:\/\/doi.org\/10.2165\/11537580-000000000-00000\n\n.","journal-title":"Pharmacoeconomics"},{"key":"825_CR27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40273-017-0532-2","volume":"35","author":"RJG Arnold","year":"2017","unstructured":"Arnold RJG, Ekins S. Ahead of our time: collaboration in modeling then and now. Pharmacoeconomics. 2017;35:975\u20136. \nhttps:\/\/doi.org\/10.1007\/s40273-017-0532-2\n\n.","journal-title":"Pharmacoeconomics"},{"key":"825_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2165\/11312720-000000000-00000","volume":"27","author":"PJ Neumann","year":"2009","unstructured":"Neumann PJ, Fang CH, Cohen JT. 30\u00a0years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics. 2009;27:861\u201372. \nhttps:\/\/doi.org\/10.2165\/11312720-000000000-00000\n\n.","journal-title":"Pharmacoeconomics"},{"key":"825_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-7525-11-151","volume":"16","author":"H Dakin","year":"2013","unstructured":"Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013;16:31. \nhttps:\/\/doi.org\/10.1186\/1477-7525-11-151\n\n.","journal-title":"Health Qual Life Outcomes"},{"key":"825_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jval.2012.03.004","volume":"15","author":"CH Ridyard","year":"2012","unstructured":"Ridyard CH, Hughes DA. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. Value Health. 2012;15:650\u20135. \nhttps:\/\/doi.org\/10.1016\/j.jval.2012.03.004\n\n.","journal-title":"Value Health"},{"key":"825_CR31","doi-asserted-by":"publisher","first-page":"A580","DOI":"10.1016\/j.jval.2013.08.1585","volume":"16","author":"A Rees","year":"2013","unstructured":"Rees A, Paisley S, Brazier J, et al. Development of the Scharr HUD (Health Utilities Database). Value Health. 2013;16:A580. \nhttps:\/\/doi.org\/10.1016\/j.jval.2013.08.1585\n\n.","journal-title":"Value Health"},{"key":"825_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/eurheartj\/ehn567","volume":"30","author":"J Leal","year":"2009","unstructured":"Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J. 2009;30:834\u20139. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehn567\n\n.","journal-title":"Eur Heart J"},{"key":"825_CR33","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2012.4230","volume":"307","author":"K Dickersin","year":"2012","unstructured":"Dickersin K, Rennie D. The evolution of trial registries and their use to assess the clinical trial enterprise. JAMA. 2012;307:1861\u20134. \nhttps:\/\/doi.org\/10.1001\/jama.2012.4230\n\n.","journal-title":"JAMA"},{"key":"825_CR34","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1056\/nejmsa053234","volume":"353","author":"DA Zarin","year":"2005","unstructured":"Zarin DA, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med. 2005;353:2779\u201387. \nhttps:\/\/doi.org\/10.1056\/nejmsa053234\n\n.","journal-title":"N Engl J Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00825-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T19:30:16Z","timestamp":1595619016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00825-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00825-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"26 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No explicit\u00a0funding was received for work involved in the preparation of this article or for participation in the Mount Hood Diabetes Network Challenge.\u00a0SK,\u00a0PC and AG were partly funded by the\u00a0National Institute for Health Research Biomedical Research Centre at the University of Oxford (grant number NIHR-BRC-1215-20008)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MW acknowledges employment by the Swedish Institute for Health Economics, which created and owns the ECHO-T2DM model and provides consulting services for its use. PC acknowledges payments for workshops on diabetes simulation modelling held alongside Mount Hood meetings. The Universities of Oxford and Melbourne have received royalties for the UKPDS Outcomes Model. PM is the managing director of Health Economics and Outcomes Research Ltd. TF developed the AdViSHE tool. All other authors (SK, FB, AT-D, IS, MT, PZ, WY, SL, WH, WS, AG, JL, ML, and AJP) report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}